Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Mirabegron as Add-on Therapy in Patients With Overactive Bladder Treated With Solifenacin: A Postmarketing Open-label Study in Japan

NCT01745094 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01745094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01745094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Mirabegron as Add-on Therapy in Patients With Overactive Bladder Treated With Solifenacin: A Postmarketing Open-label Study in Japan
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
October 1, 2012
Completion date
July 23, 2013
Enrollment
223 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder